8-KLeadership ChangesShareholder MattersExhibits & Filings

DEXCOM INC 8-K Report, Executive Changes (Jun 4, 2019)

Filed June 4, 2019For Securities:DXCM

Summary

DexCom, Inc. (DXCM) filed an 8-K on June 4, 2019, detailing key decisions made during its Annual Stockholders Meeting on May 30, 2019, and executive compensation plan adoptions. A significant development was the stockholder approval of an amendment to the Amended and Restated 2015 Equity Incentive Plan, which increases the share reserve by an additional 2,200,000 shares. This move is designed to provide flexibility in equity-based compensation and align with current tax laws, indicating a commitment to incentivizing and retaining key talent. Furthermore, the Board of Directors adopted the DexCom, Inc. Executive Deferred Compensation Plan, effective April 1, 2019. This non-qualified plan allows eligible executives, including named executive officers, to defer a portion of their base salary and annual cash bonuses, offering tax advantages and a structured way to save for retirement. The company also ratified the appointment of Ernst & Young LLP as its independent auditor and approved the advisory resolution on executive compensation, reflecting continued confidence in its financial oversight and compensation strategies.

Key Highlights

  • 1Stockholders approved an amendment to the Amended and Restated 2015 Equity Incentive Plan, reserving an additional 2,200,000 shares for issuance.
  • 2The approved amendment to the equity incentive plan aims to provide administrator flexibility with vesting during leaves of absence and conform to current tax law.
  • 3DexCom adopted a new Executive Deferred Compensation Plan, allowing eligible executives to defer salary and bonus compensation for tax and retirement savings purposes.
  • 4The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019, was ratified by stockholders.
  • 5A non-binding advisory resolution on the compensation of named executive officers was approved by stockholders.
  • 6Three Class II directors, Steven R. Altman, Barbara E. Kahn, and Jay S. Skyler, were elected to serve until their successors are elected and qualified.

Frequently Asked Questions

The amendment increases the number of shares reserved for issuance under the plan by 2,200,000. This dilutes existing shareholders to some extent, but it is intended to provide DexCom with the flexibility to continue attracting, retaining, and incentivizing key employees and executives through equity-based compensation, which is a common practice in the industry.

The plan allows eligible executives to defer a portion of their base salary (up to 75%) and annual cash bonus (up to 100%) on a pre-tax basis. This enables them to defer income taxes until they receive the payouts, typically upon separation from the company, and to save for retirement in a structured manner. DexCom may also make discretionary or matching credits to these accounts.

The ratification by stockholders signifies their confidence in the independence and quality of Ernst & Young LLP's audit services. It's a routine but important procedural step that ensures the integrity of DexCom's financial reporting for the fiscal year 2019.

The advisory vote on executive compensation was approved by a significant majority (71,011,374 in favor vs. 4,026,314 against). While the 'Say on Pay' vote is advisory, the strong approval suggests that most shareholders are in agreement with the company's executive compensation policies as disclosed.